Search research articles
Contact Us
Filters
Showing results (171-180 of 215) with videos related to
Page
of 22
Sort By:
Elife
|
November 14, 2018
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Josep M Del Campo, Ursula A Matulonis, Susanne Malander, et al.
The Lancet. Oncology
|
April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
Michael S Gordon, Daniela Matei, Carol Aghajanian, et al.
Nature Immunology
|
May 20, 2026
Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer
Han Dong, Arindam Ray, Lara K Rotter, et al.
Nature Communications
|
September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 29, 2012
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy
Shannon M McAuliffe, Stefanie L Morgan, Gregory A Wyant, et al.
Nature Communications
|
December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
Panagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
JAMA Oncology
|
July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
Panagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
JCO Precision Oncology
|
April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Page
of 22
Search research articles
Search
Showing results (171-180 of 215) with videos related to
Sort By:
Page
of 22
Elife
|
November 14, 2018
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Josep M Del Campo, Ursula A Matulonis, Susanne Malander, et al.
The Lancet. Oncology
|
April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
Michael S Gordon, Daniela Matei, Carol Aghajanian, et al.
Nature Immunology
|
May 20, 2026
Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer
Han Dong, Arindam Ray, Lara K Rotter, et al.
Nature Communications
|
September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 29, 2012
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy
Shannon M McAuliffe, Stefanie L Morgan, Gregory A Wyant, et al.
Nature Communications
|
December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
Panagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
JAMA Oncology
|
July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
Panagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
JCO Precision Oncology
|
April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Page
of 22